Ozempic vs Mounjaro: what's different for tracking your numbers
Semaglutide (Ozempic) and tirzepatide (Mounjaro) work on overlapping but different gut hormone pathways, which changes what's worth tracking.
In short: Mounjaro adds a GIP effect on top of the GLP-1 pathway Ozempic uses; both are tracked the same way, weight and glucose together.
Ozempic (semaglutide) is a GLP-1 receptor agonist. Mounjaro (tirzepatide) is a dual GIP/GLP-1 receptor agonist, meaning it acts on two gut hormone pathways instead of one. Published head-to-head trials have generally shown somewhat larger average reductions in weight and A1C with tirzepatide than with semaglutide at comparable doses, likely tied to that dual action, though individual results vary widely and either can work well for a given person.
Both are once-weekly injections that start low and step up on a schedule your prescriber sets, but the specific dose numbers and the maintenance range differ between the two. So it helps to log the actual dose each time rather than relying on memory once you've been on either for a few months: the medication names look similar in conversation, but the numbers on the pen aren't interchangeable.
Whichever one you're on, the numbers worth watching are the same: time in range, average glucose, and weight, read as a trend over weeks. Comparing your own week-to-week trend matters more than comparing yourself to someone else's results or to a trial average, since individual response to either medication varies more than the difference between them. Your prescriber decides which medication fits your history and goals.